Physalins A and B inhibit androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression

Biological and Pharmaceutical Bulletin

Volumn 34, Issue 10, 2011, Pages 1584-1588

  Han, Huiying ^a   Qiu, Li ^b   Wang, Xianghong ^c   Qiu, Feng ^d   Wong, Yongchuan ^c   Yao, Xinsheng ^d,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Guangxi Institute of Medical Plant   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^e JINAN UNIVERSITY   (China)

Author keywords

Androgen receptor; Androgen independent prostate cancer; Apoptosis; Physalin A; Physalin B

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; PHYSALIN A; PHYSALIN B; PROSTATE SPECIFIC ANTIGEN; SECOSTEROID; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; PHYSALIS; PHYSALIS ALKEKENGI; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGEN ANTAGONISTS; ANDROGENS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MOLECULAR TARGETED THERAPY; PHYSALIS; PHYTOTHERAPY; PLANT PREPARATIONS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SECOSTEROIDS; SIGNAL TRANSDUCTION;

EID: 80053507350     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.34.1584     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., CA Cancer J. Clin., 58, 71-96 (2008).
2. Denmeade S. R., Isaacs J. T., Nat. Rev. Cancer, 2, 389-396 (2002).
3. Feldman B. J., Feldman D., Nat. Rev. Cancer, 1, 34-45 (2001).
4. Linja M. J., Savinainen K. J., Saramäki O. R., Tammela T. L., Vessella R. L., Visakorpi T., Cancer Res., 61, 3550-3555 (2001).
5. Tilley W. D., Buchanan G., Hickey T. E., Bentel J. M., Clin. Cancer Res., 2, 277-285 (1996).
6. Han H. Y., Wang X. H., Wang N. L., Ling M. T., Wong Y. C., Yao X. S., J. Agric. Food Chem., 56, 6928-6935 (2008).
7. Qiu L., Zhao F., Jiang Z. H., Chen L. X., Zhao Q., Liu H. X., Yao X. S., Qiu F., J. Nat. Prod., 71, 642-646 (2008).
8. Chinese Pharmacopoeia Committee, Pharmacopoeia of the People's Republic of China, 1, 250-251 (2005).
9. Chiang H. C., Jaw S. M., Chen P. M., Anticancer Res., 12, 1155-1162 (1992a).
10. Fang L., Chai H. B., Castillo J. J., Soejarto D. D., Farnsworth N. R., Cordell G. A., Pezzuto J. M., Kinghorn A. D., Phytother. Res., 17, 520-523 (2003).
11. Lee C. C., Houghton P., J. Ethnopharmacol., 100, 237-243 (2005).
12. Magalhães H. I., Veras M. L., Torres M. R., Alves A. P., Pessoa O. D., Silveira E. R., Costa-Lotufo L. V., de Moraes M. O., Pessoa C., J. Pharm. Pharmacol., 58, 235-241 (2006).
13. Cheung H. W., Jin D. Y., Ling M. T., Wong Y. C., Wang Q., Tsao S. W., Wang X., Cancer Res., 65, 1450-1458 (2005).
14. Kwok W. K., Ling M. T., Lee T. W., Lau T. C., Zhou C., Zhang X., Chua C. W., Chan K. W., Chan F. L., Glackin C., Wong Y. C., Wang X., Cancer Res., 65, 5153-5162 (2005).
15. Thalmann G. N., Anezinis P. E., Chang S. M., Zhau H. E., Kim E. E., Hopwood V. L., Pathak S., Von Eschenbach A. C., Chung L. W., Cancer Res., 54, 2577-2581 (1994).
16. Sramkoski R. M., Pretlow T. G., Giaconia J. M., Pretlow T. P., Schwartz S., Sy M. S., Marengo S.R.,Rhim J. S., Zhang D., Jacobberger J.W. Cell. Dev. Biol. Anim., 35, 403-409 (1999).
17. Nicholson D. W., Ali A., Thornberry N. A., Vaillancourt J. P., Ding C. K., Gallant M., Gareau Y., Griffin P. R., Labelle M., Lazebnik Y. A., Munday N. A., Raju S. M., Smuson M. S., Yamin T. T., Yu V. L., Miller D. K., Nature (London), 376, 37-43 (1995).
18. Widmann C., Gibson S., Jarpe M. B., Johnson G. L., Physiol. Rev., 79, 143-180 (1999).
19. Hu X., Janssen W. E., Moscinski L. C., Bryington M., Dangsupa A., Rezai-Zadeh N., Babbin B. A., Zuckerman K. S., Cancer Res., 61, 6290-6296 (2001).
20. van den Brink M. R., Kapeller R., Pratt J. C., Chang J. H., Burakoff S. J., J. Biol. Chem., 274, 11178-11185 (1999).
21. Wang X., Martindale J. L., Holbrook N. J., J. Biol. Chem., 275, 39435-39443 (2000).
22. Sanchez-Prieto R., Rojas J. M., Taya Y., Gutkind J. S., Cancer Res., 60, 2464-2472 (2000).
23. Deschesnes R. G., Huot J., Valerie K., Landry J., Mol. Biol. Cell, 12, 1569-1582 (2001).
24. Mandlekar S., Yu R., Tan T. H., Kong A. N., Cancer Res., 60, 5995-6000 (2000).
25. Stadheim T. A., Kucera G. L., Leuk. Res., 26, 55-65 (2002).
26. Culig Z., Hobisch A., Hittmair A., Peterziel H., Cato A. C., Bartsch G., Klocker H., Prostate, 35, 63-70 (1998).
27. Chen C. D., Welsbie D. S., Tran C., Baek S. H., Chen R., Vessella R., Rosenfeld M. G., Sawyers C. L., Nat. Med., 10, 33-39 (2004).
28. Kim J., Coetzee G. A., J. Cell. Biochem., 93, 233-241 (2004).
29. Liao X., Tang S., Thrasher J. B., Griebling T. L., Li B., Mol. Cancer Ther., 4, 505-515 (2005).
30. Haag P., Bektic J., Bartsch G., Klocker H., Eder I. E., J. Steroid Biochem. Mol. Biol., 96, 251-258 (2005).
31. Edwards J., Bartlett J. M., BJU Int., 95, 1327-1335 (2005).
32. Edwards J., Bartlett J. M., BJU Int., 95, 1320-1326 (2005).
33. Abreu-Martin M. T., Chari A., Palladino A. A., Craft N. A., Sawyers C. L., Mol. Cell. Biol., 19, 5143-5154 (1999).